

## **Product datasheet for SR302748**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## CD229 (LY9) Human siRNA Oligo Duplex (Locus ID 4063)

## **Product data:**

**Guaranteed:** 

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

**Quality Control:** Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

RefSeq: NM 001033667, NM 001261456, NM 001261457, NM 002348

UniProt ID: Q9HBG7

**Synonyms:** CD229; hly9; mLY9; SLAMF3

Components: LY9 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 4063)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492)

and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006

[PubMed 16365421]).[supplied by OMIM, Mar 2008]

Performance OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will

provide at least 70% or more knockdown of the target mRNA when used at 10 nM

concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT

positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data

required).

